CD44 is the principal cell surface receptor for hyaluronic acid (HA), a ubiquitous ECM polysaccharide which profoundly influences stromal and infiltrating cell behavior and plays a major role in the maintenance of tissue homeostasis. HA accumulation is increased during periods of cell proliferation as in inflammation, tissue remodeling and regeneration, development and invasion by malignancy. CD44-HA interaction is therefore believed to regulate multiple cellular responses as a results of tumor formation in vivo and that this effect is CD44-HA interaction dependent. The applicant has observed expression of the intracellular domain of CD44 is required for tumor cell migration on HA and have shown that glycosylation provides a potent regulatory mechanism for CD44-HA interaction, affecting both the standard form of CD44 (CD44H) and differentially spliced exons encoding a segment of the membrane proximal domain. The applicant will determine the mechanisms by which glycosylation regulates CD44-HA interaction and identify specific carbohydrate groups which enhance or inhibit binding. Studies will extend these experiments to examine the effects of disrupting tumor cell CD44-ECM HA interaction using soluble recombinant CD44 and anti CD44 antibodies. Specifically, the applicant will address the role of CD44 in tumor cell adhesion to host tissue endothelium and stroma as well as in tumor angiogenesis. Finally, the applicant has developed a transgenic mouse model which has tissue specific CD44 deficiency in the skin. Availability of this model will provide the possibility to address the physiologic function of CD44 in HA metabolism, regulation of tissue homeostasis, inflammation and tumorigenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA055735-10
Application #
6375919
Study Section
Pathobiochemistry Study Section (PBC)
Project Start
1992-02-01
Project End
2002-04-30
Budget Start
2001-05-01
Budget End
2002-04-30
Support Year
10
Fiscal Year
2001
Total Cost
$250,199
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Fiore, Emilio; Fusco, Carlo; Romero, Pedro et al. (2002) Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21:5213-23
Yu, Wei-Hsuan; Woessner Jr, J Frederick; McNeish, John D et al. (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307-23
Yu, Q; Stamenkovic, I (2001) Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 158:563-70
Stamenkovic, I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10:415-33
Peterson, R M; Yu, Q; Stamenkovic, I et al. (2000) Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol 156:2159-67
Biancone, L; Cantaluppi, V; Boccellino, M et al. (1999) Activation of CD40 favors the growth and vascularization of Kaposi's sarcoma. J Immunol 163:6201-8
Biancone, L; Stamenkovic, I; Cantaluppi, V et al. (1999) Expression of L-selectin ligands by transformed endothelial cells enhances T cell-mediated rejection. J Immunol 162:5263-9
Yu, Q; Stamenkovic, I (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13:35-48
Skelton, T P; Zeng, C; Nocks, A et al. (1998) Glycosylation provides both stimulatory and inhibitory effects on cell surface and soluble CD44 binding to hyaluronan. J Cell Biol 140:431-46
Zeng, C; Toole, B P; Kinney, S D et al. (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77:396-401

Showing the most recent 10 out of 43 publications